Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuncell-LC in Refractory Metastatic Colorectal Cancer
NCT03220984Phase 2Unknown
- Sponsor
- Gangnam Severance Hospital
- Start
- Mar 2017
- Primary completion
- Mar 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of immuncell-lc in metastatic colorectal cancer (mCRC), sponsored by Gangnam Severance Hospital. Primary endpoint: Disease Control Rate at 17 weeks. Status: unknown.
02
Drugs
immuncell-lc
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03220984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03220984.